Racura Oncology (ASX:RAC) Surges 8% as RC220 Trial Cleared to Double Dosage Level

Racura Oncology Surges on Trial Update

Racura Oncology (ASX: RAC) climbed 8.66 per cent on Friday to close at A$2.76, after the independent Safety Review Committee cleared the company to double the dosage level in its CPACS Phase 1 cancer trial. The first three patients in Cohort 1 showed no dose-limiting toxicities and remain alive despite their advanced metastatic cancers, opening the door for Cohort 2 at 80 mg/m² (up from the starting 40 mg/m²) under an updated trial protocol that includes an initial lead-in safety monotherapy cycle of doxorubicin. The stock is now up roughly 94 per cent over the past year, yet still sits around 44 per cent below its all-time high of A$4.90, hit in October 2025. The question for investors is whether Friday’s bounce marks the next leg up or simply a pause.

What are the Best ASX Stocks to invest in right now?

Why RC220’s Dual-Action Mechanism Sets Racura Apart

RC220 is Racura’s proprietary formulation of (E,E)-bisantrene, a small molecule anticancer compound that targets a key cancer growth regulator called MYC. What makes it interesting is that the CPACS trial isn’t only testing whether the drug fights cancer. It is also testing whether RC220 can protect the heart from damage caused by doxorubicin, one of the most widely used chemotherapy drugs in the world.

That may sound technical, but anthracycline chemotherapies like doxorubicin damage the heart muscle in a meaningful share of patients. Many either receive lower doses than ideal or stop treatment because of the cardiac risk. If RC220 can genuinely shield the heart while also boosting anticancer activity, it solves two problems at once. We believe this dual mechanism separates Racura from the typical single-mechanism biotech story and broadens the commercial opportunity considerably.

Trial Progress and Cash Runway Tell a Reassuring Story

The Cohort 1 readout was about as clean as biotech investors could hope for at this stage. Three patients dosed, zero dose-limiting toxicities, and all are still alive despite advanced metastatic solid tumours at enrolment. Screening for Cohort 2 is now underway across sites in Australia, Hong Kong and South Korea.

Racura is also sitting on A$19.38 million in cash, enough to fund operations through calendar year 2027. For a pre-revenue biotech, that removes the most common near-term risk of being forced into a dilutive raise at a weak share price.

Beyond CPACS, the company has two more shots on goal. The HARNESS-1 trial is testing RC220 in EGFR-mutant lung cancer alongside AstraZeneca’s osimertinib, and its Phase 3 trial in relapsed/refractory acute myeloid leukaemia is expected to open for patient recruitment in late 2026.

The Investor’s Takeaway for Racura Oncology

There’s no getting around it. Racura is a speculative, pre-revenue biotech, and Phase 1 drugs have a high failure rate on the path to commercial approval. With a market cap of around A$516 million, the stock is already pricing in meaningful clinical success, so the entry isn’t cheap.

The bull case is straightforward. If the dual mechanism holds up through Cohort 2 and the Phase 3 AML program launches on schedule, RC220 has the kind of profile that can re-rate the stock substantially. The bear case is equally real. Three patients are a small sample, and early biotech signals have a long history of being disappointing once trials scale up.

For risk-tolerant biotech investors, the 44 per cent pullback combined with de-risking trial data may offer a better entry than chasing October’s peak. More cautious investors may prefer to wait for Cohort 2 readouts before adding exposure.